Running out of bullets: The challenging management of acute hepatitis and SARS‐COV‐2 from the SMatteo COvid19 Registry (SMACORE)

Liver impairment is frequent in patients with novel coronavirus disease (COVID‐19) and direct viral tropism for the liver has been proven. Since several of the currently administered drugs against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are possibly hepatotoxic, the management o...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2020-11, Vol.40 (11), p.2655-2659
Main Authors: Colaneri, Marta, Valsecchi, Pietro, Perotti, Luciano, Ludovisi, Serena, Seminari, Elena, Pieri, Teresa Chiara, Sacchi, Paolo, Bruno, Raffaele
Format: Article
Language:English
Subjects:
Brief Definitive Report
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - blood
COVID-19 - complications
COVID-19 - therapy
HBV
Hemoperfusion
Hepatitis
Hepatitis B - blood
Hepatitis B - complications
Hepatitis B - therapy
Humans
Hyperbilirubinemia
Liver
Liver diseases
Male
Middle Aged
Projectiles
Registries
Respiratory diseases
SARS-CoV-2 - isolation & purification
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Toxins
Tropism
Viral diseases
Viral Hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver impairment is frequent in patients with novel coronavirus disease (COVID‐19) and direct viral tropism for the liver has been proven. Since several of the currently administered drugs against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are possibly hepatotoxic, the management of patients with COVID‐19 and liver failure is still an almost unexplored field. Taking this challenging case of acute HBV with persistent hyperbilirubinemia and SARS‐COV‐2 infection with respiratory distress as a starting point, we here loop through this condition. Where the available therapeutic options are scarce, we here propose hemoperfusion (HP) as an attractive alternative to both delay any late‐stage progression of hyper inflammation process in COVID‐19 and remove the toxins involved in acute liver failure.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14609